GREENSBORO, N.C., Sept. 17, 2012 /PRNewswire/ -- Merz, Inc. (U.S. affiliate of Merz Pharma Group) today announced the appointment of Cynthia Schwalm has as vice president, neurology effective immediately. Schwalm will be responsible for the Merz's growing neurology business unit in the U.S., which includes the recently acquired product CUVPOSA®.
"Cynthia brings national as well as international experience, in developing and commercializing pharmaceutical products. We are extremely pleased to have her join the Merz team and are confident she will make immediate and important contributions to steer the future growth of our neurology business and the company as a whole," said Bill Humphries, president & CEO of Merz, Inc.
Humphries noted that he will name his entire North American Leadership Team within the next few months as Merz, Inc. and its U.S. affiliates continue to undergo integration in preparation for accelerated growth opportunities across all business units.
Prior to joining Merz, Schwalm was the Senior Advisor to the Chief Executive Officer at Chimerix, Inc. She has held various international commercial leadership and general management positions with Optimer, Eisai, Amgen, and Johnson & Johnson. Schwalm brings with her 30 years of experience in the pharmaceutical and healthcare industry, with commercialization experience in movement disorders and neurology including pain management, Alzheimer's disease, and epilepsy including Lennox Gaustaut syndrome.
Schwalm obtained her Bachelor of Science in Nursing from the University of Delaware in Newark, DE. She also earned her Executive Master of Business Administration from the Wharton School of Business from the University in Pennsylvania in Philadelphia, PA. Schwalm is a member for Beth Abraham Family Health Services Board and Sarah Cannon Oncology Research Institute Board. She will be based out of the office in Greensboro, NC.
About Merz, Inc.
Merz, Inc. is responsible for developing and commercializing products in the U.S. for Merz Pharma Group. Areas of therapeutic focus include Neurology, Physiatry, Dermatology, Aesthetics, and Podiatry.
About Merz Pharma Group
Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses and thereby assume a leading role in the field of Alzheimer research. Another important area of competency of Merz is Clinical Dermatology and Aesthetic Medicine. Merz is also active in the Health sector outside of the pharmacy. In the field of consumer products, with its established brands of tetesept® and Merz Spezial®, Merz Consumer Care is a leading provider of products for self-medication, nutritional supplements and skin care in the German-speaking area. Merz Pharma Group is a privately owned company, founded in 1908 in Frankfurt, Germany.
SOURCE Merz, Inc.